Richard J. Benjamin, the Chief Medical Officer of Cerus Corp (NASDAQ:CERS), executed a series of stock transactions between March 5 and March 9, 2026, that resulted in the sale of 125,964 shares of common stock for approximately $202,334.
The dispositions occurred over several trades and at varying prices. The most substantial set of sales took place on March 5, when Benjamin sold 61,233 shares in multiple transactions at prices ranging from $2.02 to $2.17 per share. On March 6 he sold 24,235 shares at a single price of $2.0055. The final tranche recorded on March 9 consisted of 40,426 shares sold in multiple transactions at prices between $1.855 and $1.91 per share. Across the March 5-9 window, the per-share sale prices ranged from $1.855 to $2.17.
In addition to these sales, Benjamin received 55,220 shares of Cerus common stock on March 5 through a non-derivative transaction at zero cost. Following completion of the recorded transactions, his direct ownership in Cerus stands at 879,101 shares.
These insider moves come amid recent share-price volatility. Cerus stock fell 9.4% over the prior week, although the stock remains up 63.6% over the past six months. A referenced InvestingPro analysis notes that CERS has a beta of 1.53, indicating a degree of historical volatility relative to the broader market. The company is described as a $374 million biotech firm in the material provided.
Separately, Cerus reported solid operating results for the fourth quarter of 2025. The company posted revenues of $233.8 million for Q4, a 16% increase compared with the same period a year earlier. Reported earnings per share for the quarter were -$0.01, which matched market expectations. The revenue growth was highlighted as a notable element of the quarter, and the EPS result was characterized as in line with estimates.
Within the information supplied, analysts are described as observing steady growth for Cerus, although no specific analyst upgrades or downgrades are mentioned. The material also indicates that investor reaction has been generally positive given the described stock behavior, and it frames the financial results as reinforcing the company’s operational momentum and strategic direction.
Summary: Benjamin carried out multiple sales totaling 125,964 shares for roughly $202,334 between March 5 and March 9, 2026, while also receiving 55,220 shares at no cost. Post-transactions, his direct holdings equal 879,101 shares. These moves occur against a backdrop of recent stock volatility and a fourth-quarter revenue gain of 16% year over year.
Note: The reporting here reflects only the transaction quantities, prices, dates, company financials, and attributed analysis as provided in the source material.